Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives

Abstract

The progestational steroid norgestrel was synthesized and tested between 1960 and 1965 through an international cooperation between Wyeth, USA and Schering, Berlin. It is a mixture of two “enantiomers,” with only one form (designated as levonorgestrel) biologically active. When taken orally, it is rapidly absorbed, not subjected to a “first-pass” effect and is approximately 90% bioavailable, with a circulating half-life around 15 hours. Its contraceptive action is exerted at the central (hypothalamic) and peripheral (cervical mucus and endometrium) levels. Levonorgestrel (LNG), alone or in combination with ethinyl estradiol (EE), is the most widely employed contraceptive progestin: it is used in combined oral contraceptives, progestogen-only pills, long-acting contraceptive implants, intrauterine contraceptive systems and in emergency contraception. It is also the steroid of choice for new oral contraceptive regimens aimed at reducing the frequency of bleeding episodes. This novel approach, already tried more than 30 years ago, gained interest around the year 2000 when surveys of women’s attitudes toward monthly menstrual bleeding started to show a major change: more and more women declared that they would welcome a hormonal contraceptive method that reduced bleeding episodes to 4, 2 or even 1 per year. At this point, while the debate on the significance and “usefulness” of menstruation went on, attention focused on new regimens. The first new modality consisted of changing the 7-day medication-free interval, either shortening it to fewer than 7 days, or by the administration of low-dose estrogens during the interval between packages. Then, continuous administration regimens started to be investigated. This, however, did not happen suddenly, since, in specific situations, doctors had for years empirically utilized various continuous administration regimens. The first extended-cycle oral contraceptive regimen introduced in clinical practice is an 84-day regimen that results in bleeding only 4 times a year. A commercial product specifically packed for continuous use is now available in Europe and contains 30 μg EE and 150 μg LNG. In a variation of this regimen, after administration of the same combination for 84 days, women are given 7 pills containing 10 μg EE. A 6-monthly regimen has also been tested in a small study using EE 20 μg plus LNG 100 μg taken with and without a hormone-free interval. Women in the continuous group reported significantly fewer bleeding days requiring protection and were more likely to have amenorrhea; in addition they also reported significantly fewer days of bloating and menstrual pain. A yearly regimen is now being developed. Each pill of this novel formulation contains EE 20 μg and LNG 90 μg to be taken continuously for 364 days (13 cycles) per year. A phase III trial has now evaluated safety, efficacy and menses inhibition. At the end of the 1-year trial amenorrhea was present in 58.7% of the women and a complete absence of bleeding in 79.0%. Overall, the number of bleeding and spott...

Menstrual Adjustment Administering Hormonal Agents: A Survey of Iranian Pilgrim Women During Long-Term Travel

“…Until date, there is no other study about the efficiency of this agent in delaying menstrual cycle during a pilgrimage in Iranian women. Side effects of the studied hormonal agents were minimal according to our report that is correspondent with previous studies (8,12,29). No major side effect of COCs such as stroke or deep vein thrombosis was reported.…”

Contraception for women with epilepsy: counseling, choices, and concerns

“…Such “long-cycle” or “extended-cycle” regimens have been proven safe and convenient, and are becoming increasingly popular among fertile women. 61 , 62 Recently, a COC designed for an 84-day regimen that results in bleeding only four times a year has been introduced. HC preparations for even longer cycles, 6 and 12 months, are currently being developed.…”

Role of the levonorgestrel intrauterine system in effective contraception

“…LNG (D[-]l-17β-hydroxy-17α-ethinyl-13β-ethyl-4-gonen-3-one), a synthetic second-generation progestin chemically derived from 19-nortestosterone,13 is six times more potent than progesterone, but also has strong androgenic properties and binding potential to the sex hormone-binding globulin 14. It also has variable binding affinity to various human steroid receptors, including glucocorticoid receptors and mineralocorticoid receptors, and minimal binding to estrogen receptors 15.…”